Jean-Michel Dogné on The Aspirin Dosing after Trump’s Announcement
Jean-Michel Dogné, Full Professor and Dean of the Faculty of Medicine at Namur University, shared on LinkedIn:
”Approximations and blatant errors…
From the great Trump
- The aspirin (ASA) does not “thin” or “liquefy” the blood!
Acetylsalicylic acid has no effect on blood viscosity.
Its mechanism of action is well known:
- inhibition of platelet aggregation,
- by irreversibly blocking platelet COX-1,
- leading to a decrease in thromboxane A₂ synthesis.
Talking about “thick blood” or “thin blood” is therefore a misleading simplification with no pathophysiological basis.
2. In cardiovascular (secondary) prevention, we are not talking about high doses!
The recommendations are very clear:
- Low-dose ASA, generally 75 to 100 mg per day.
Furthermore, in patients aged ≥ 70 with no history of cardiovascular disease, data show no net benefit from low-dose ASA and a significant increase in major bleeding!
In practice, the recommendations therefore advise against initiating ASA for primary prevention in these patients.”

Stay updated with Hemostasis Today.
-
Nov 14, 2026, 23:57Jamie S. Y. Ho: Exploring the Mechanisms of Arterial Thrombosis and the Evolution of Antithrombotic Therapy
-
Nov 14, 2026, 23:53Jacopo Imberti: The Past, Present and Future of Arterial Thrombosis Research
-
Nov 14, 2026, 23:48Shrouk Ramadan: Joining the Editorial Review Board of Clinical and Applied Thrombosis and Hemostasis
-
Nov 14, 2026, 23:46Habib Bennaceur: Moving Towards Fewer Limitations for People Living With Haemophilia
-
Nov 14, 2026, 23:44Paul Healy: EU Approves Frehemgo for Haemophilia A
-
Nov 14, 2026, 23:43Mehak Trehan: ASH 2026 Benign Hematology – Ten Abstracts Through an Indian Lens
-
Nov 14, 2026, 23:33Felipe Magalhaes Furtado: Artificial Intelligence Advances PNH Clone Detection Through Machine Learning
-
Nov 14, 2026, 23:33Mona Alfaraj: International Pathology Day Promotes Education in Hemoglobinopathy Diagnostics
-
Nov 14, 2026, 23:33Alexandros Makis: Exploring Vascular Mechanisms and Therapeutic Targets in β-Thalassemia